Sucralfate 4% in Emulsifying ointment
Prescription only
Requires a prescription from a doctor or prescriber
Ointment
4%
Topical
Local preparations for anal and rectal disorders
Active ingredients:
Sucralfate
1 safety notice
Safety information for pregnancy and breastfeeding
Category B
Animal studies show no risk; no adequate human studiesPregnancy
Use in pregnancy
This drug is considered a pregnancy Category B drug.
This drug is considered a pregnancy Category B drug.
No harm to the fetus has been observed in the abovementioned studies.
Sufficient and well-controlled clinical trials have not been performed in pregnant women.
Due to the fact that the results of animal studies are not always relevant to human response, sucralfate should be used during pregnancy only if it is deemed essential for the mother's health [FDA label].
Breastfeeding
Use in nursing
Whether this drug is excreted in human milk is currently unknown.
Whether this drug is excreted in human milk is currently unknown.
Many drugs are excreted in breast milk, therefore, if sucralfate is administered to a lactating and nursing woman, caution should be observed [FDA label].
Always consult your doctor or midwife before taking any medicine during pregnancy or while breastfeeding. Source: DrugBank (CC BY-NC 4.0).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Source: MHRA Products DatabaseOGL 3.0
Updated 3 months ago(16 Jan 2026)Safety monitoring data
Yellow Card reports
MHRA
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Sucralfate
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
EMA
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Sucralfate
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Show details
Therapeutically similar medicines
Show details
Glyceryl trinitrate 0.2% cream
Cream
0.2%
Same BNF section
Diltiazem 0.4% ointment
Ointment
0.4%
Same BNF section
Diltiazem 1% cream
Cream
1%
Same BNF section
Diltiazem 4% ointment
Ointment
4%
Same BNF section
Sucralfate 1g/30ml enema
Other
1g/30ml
Same BNF section
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Show details
Loading prescribing data...
Clinical guidelines and formulary information
British National Formulary
Sucralfate
BNF
Drug monograph — bnf.nice.org.ukSource: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Show details
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
Show details
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA).
Active and completed clinical studies from ClinicalTrials.gov
Show details
Searching UK clinical trials...
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
6-20 h
Mechanism
The mechanism of action of this drug in the healing duodenal ulcers is not yet c…
Food interactions
2 warnings
Human targets
4 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
0.001%
This drug is absorbed from the gastrointestinal tract in very minimal quantities.[FDA…
Half-life
6-20 h
The half-life is not known. In animals, the elimination half-life of the sucrose component of this drug is from 6-20 h F4537.
Protein binding
Sucralfate is bound to plasma proteins, especially albumin and transferrin F4519.
Volume of distribution
This drug is absorbed in a very small quantity, and normally localizes to inflamed gastrointestinal lesions [FDA label].
Metabolism
This drug is absorbed in very small quantities and is not significantly metabolized [FDA label, F4519].
Elimination
48 hours
The negligible amount of this drug that is absorbed is excreted mainly in the urine within 48 hours [FDA label, F4537].
Clearance
Sucralfate contains aluminum. The administration of sucralfate in non-dialyzed chronic renal failure patients warrants careful consideration…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Status:
Approved
Investigational
Small molecule
About this compound
Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia [A177655]. It is considered a cytoprotective agent, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances [A177655, F4519].
Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073][L6076].
Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073][L6076].
Properties:
View FDA drug labelsolid
Avg. mass: 1558.67 Da
DrugBank indication
The sucralfate suspension [FDA label] and tablet F4534 are used for the treatment of active duodenal ulcer for up to 8 weeks. The tablet form may be used at a lower dose for healed duodenal ulcers, for the purpose of maintaining healing and preventing recurrence [F4519, F4534].
Sucralfate is also used in the prevention and/or treatment of gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia [A177655, F4519].
Sucralfate is also used in the prevention and/or treatment of gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia [A177655, F4519].
Also known as(14)
Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
Sucralfat
Sucralfate
Sucralfato
Sucralfatum
3.4.23.1
Pepsinogen-5
Basic fibroblast growth factor
Dosage forms(52)
Tablet (Oral) — 1.0000 g
Tablet (Oral) — 1000.00 mg
Tablet, chewable (Buccal) — 500 mg
Powder (Oral) — 1 G
Powder (Oral) — 2 G
Suspension (Oral) — 20 %
Tablet (Oral) — 1 g
Tablet, coated (Oral)
Molecular properties(19)
Drug interactions(861)
Known interactions with other medications. Always consult a healthcare professional.
Calcitriol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Calcitriol.
Calcifediol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Calcifediol.
Ergocalciferol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Ergocalciferol.
Cholecalciferol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Cholecalciferol.
Paricalcitol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol.
Dihydrotachysterol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Dihydrotachysterol.
Alfacalcidol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Alfacalcidol.
Seocalcitol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Seocalcitol.
Inecalcitol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Inecalcitol.
Becocalcidiol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Becocalcidiol.
Eldecalcitol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Eldecalcitol.
1alpha,24S-Dihydroxyvitamin D2
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with 1alpha,24S-Dihydroxyvitamin D2.
Elocalcitol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Elocalcitol.
Maxacalcitol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Maxacalcitol.
Doxercalciferol
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Doxercalciferol.
The serum concentration of Sucralfate can be increased when it is combined with Vitamin D.
1alpha-Hydroxyvitamin D5
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with 1alpha-Hydroxyvitamin D5.
Previtamin D(3)
Unknown severity
The serum concentration of Sucralfate can be increased when it is combined with Previtamin D(3).
Moxifloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Grepafloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sucralfate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pefloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ciprofloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Trovafloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nalidixic acid
Moderate
Sucralfate can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sucralfate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sucralfate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lomefloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gatifloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Norfloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levofloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gemifloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sucralfate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sparfloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Temafloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fleroxacin
Moderate
Sucralfate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sucralfate can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Garenoxacin
Moderate
Sucralfate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nemonoxacin
Moderate
Sucralfate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Flumequine
Moderate
Sucralfate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Enrofloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Orbifloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sarafloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Difloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pazufloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Prulifloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Delafloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sitafloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxolinic acid
Moderate
Sucralfate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rufloxacin
Moderate
Sucralfate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Showing 50 of 861 interactions
Food & lifestyle interactions
Empty Stomach
Take on an empty stomach. Take at least 1 hour before or 2 hours after meals.
Advice
Take separate from antacids. Take at least 30 minutes before or after antacids.
Toxicity & overdose
Overdose
Overdosage has never been observed with sucralfate F4519. It is unlikely, as administering a maximum dose of up to 12 g/kg/body weight in several animal species did not result in death. The lethal dose could not be determined in these studies F4519.
It is likely that overdose of sucralfate in humans would result in constipation, and supportive treatment would be advised F4519.
Use in pregnancy
This drug is considered a pregnancy Category B drug. Studies have been performed in rodents and rabbits at doses up to 50 times the recommended human dose. No harm to the fetus has been observed in the abovementioned studies. Sufficient and well-controlled clinical trials have not been performed in pregnant women.
Due to the fact that the results of animal studies are not always relevant to human response, sucralfate should be used during pregnancy only if it is deemed essential for the mother's health [FDA label].
Use in nursing
Whether this drug is excreted in human milk is currently unknown. Many drugs are excreted in breast milk, therefore, if sucralfate is administered to a lactating and nursing woman, caution should be observed [FDA label].
Carcinogenesis
24 month toxicity studies were performed in rodents, and the dose of sucralfate reached up to 1 g/kg (equivalent to 12 times the recommended human dose). No signs of sucralfate-related tumors were noted[FDA label].
Overdosage has never been observed with sucralfate F4519. It is unlikely, as administering a maximum dose of up to 12 g/kg/body weight in several animal species did not result in death. The lethal dose could not be determined in these studies F4519.
It is likely that overdose of sucralfate in humans would result in constipation, and supportive treatment would be advised F4519.
Use in pregnancy
This drug is considered a pregnancy Category B drug. Studies have been performed in rodents and rabbits at doses up to 50 times the recommended human dose. No harm to the fetus has been observed in the abovementioned studies. Sufficient and well-controlled clinical trials have not been performed in pregnant women.
Due to the fact that the results of animal studies are not always relevant to human response, sucralfate should be used during pregnancy only if it is deemed essential for the mother's health [FDA label].
Use in nursing
Whether this drug is excreted in human milk is currently unknown. Many drugs are excreted in breast milk, therefore, if sucralfate is administered to a lactating and nursing woman, caution should be observed [FDA label].
Carcinogenesis
24 month toxicity studies were performed in rodents, and the dose of sucralfate reached up to 1 g/kg (equivalent to 12 times the recommended human dose). No signs of sucralfate-related tumors were noted[FDA label].
How it works
Mechanism of action
The mechanism of action of this drug in the healing duodenal ulcers is not yet completely defined, however, there are several probable mechanisms that adequately describe the healing activity of sucralfate. There is evidence that sucralfate acts locally to aid in tissue healing, and not systemically [FDA label].
Studies in both humans and animals have indicated that sucralfate forms a complex that binds to protein-rich exudate found on the surface of ulcers. It binds to albumin and fibrinogen [A11831][A177685] preventing blood clot lysis by stomach acid (hydrochloric acid). Sucralfate increases the tissue levels of fibroblast growth factors and epidermal growth factors,[A16738][A16741] leading to an increase in prostaglandins at the gastrointestinal tract lining, which promotes the healing of gastrointestinal ulcers.[A177655]
In the laboratory setting, a sucralfate-albumin film provides a barrier against the entry of hydrogen ions, which are a component of gastric acid. In humans, sucralfate, given at therapeutic doses for ulcers, decreases pepsin activity in gastric fluids by 32% [FDA label]. Pepsin has been shown to be damaging to tissues, further aggravating ulcer lesion inflammation [A177667]. Bile salts have been implicated in mucosal injury to the gastrointestinal tract [A177697][A177700]. Sucralfate has also been shown to adsorb bile salts in the laboratory, setting, which could further contribute to its beneficial effects in ulcer healing [FDA label].
Studies in both humans and animals have indicated that sucralfate forms a complex that binds to protein-rich exudate found on the surface of ulcers. It binds to albumin and fibrinogen [A11831][A177685] preventing blood clot lysis by stomach acid (hydrochloric acid). Sucralfate increases the tissue levels of fibroblast growth factors and epidermal growth factors,[A16738][A16741] leading to an increase in prostaglandins at the gastrointestinal tract lining, which promotes the healing of gastrointestinal ulcers.[A177655]
In the laboratory setting, a sucralfate-albumin film provides a barrier against the entry of hydrogen ions, which are a component of gastric acid. In humans, sucralfate, given at therapeutic doses for ulcers, decreases pepsin activity in gastric fluids by 32% [FDA label]. Pepsin has been shown to be damaging to tissues, further aggravating ulcer lesion inflammation [A177667]. Bile salts have been implicated in mucosal injury to the gastrointestinal tract [A177697][A177700]. Sucralfate has also been shown to adsorb bile salts in the laboratory, setting, which could further contribute to its beneficial effects in ulcer healing [FDA label].
Pharmacodynamics
This drug aids in the healing of duodenal ulcers, relieving painful inflammation by creating a protective mechanical barrier between the lining or skin of the gastrointestinal tract and damaging substances [A177655]. In addition, sucralfate acts to increase levels of growth factors locally, and also causes an increase in prostaglandins which are important in the healing of the mucosa (lining) of the gastrointestinal tract [A177655].
Pharmacokinetics
How the body processes this drug — absorption, distribution, metabolism, and elimination
Absorption
This drug is absorbed from the gastrointestinal tract in very minimal quantities.[FDA label] The adsorbed sulfated disaccharide is excreted in the urine F4519. This drug contains aluminum and after the administration of 1 g of sucralfate 4 times per day, about 0.001% to 0.017% of this aluminum content is absorbed in patients with normal renal function.F4519 This number is expected to increase in those with impaired renal function.F4519
Half-life
The half-life is not known. In animals, the elimination half-life of the sucrose component of this drug is from 6-20 h F4537.
Protein binding
Sucralfate is bound to plasma proteins, especially albumin and transferrin F4519.
Volume of distribution
This drug is absorbed in a very small quantity, and normally localizes to inflamed gastrointestinal lesions [FDA label].
Metabolism
This drug is absorbed in very small quantities and is not significantly metabolized [FDA label, F4519].
Route of elimination
The negligible amount of this drug that is absorbed is excreted mainly in the urine within 48 hours [FDA label, F4537].
Clearance
Sucralfate contains aluminum. The administration of sucralfate in non-dialyzed chronic renal failure patients warrants careful consideration from the treating physician as the excretion of absorbed aluminum may be decreased, causing possible aluminum toxicity F4519.
In dialyzed patients diagnosed with chronic renal failure, aluminum toxicity related to sucralfate has been observed and reported. The daily amount of aluminum ingestion (including sucralfate) should be carefully examined before administering sucralfate in combination with other drugs also containing aluminum, including various antacids F4519.
In dialyzed patients diagnosed with chronic renal failure, aluminum toxicity related to sucralfate has been observed and reported. The daily amount of aluminum ingestion (including sucralfate) should be carefully examined before administering sucralfate in combination with other drugs also containing aluminum, including various antacids F4519.
Drug targets(4)
Proteins and enzymes this drug interacts with in the body
Pepsin A-5
PGA5
inhibitor
Specific functionaspartic-type endopeptidase activity
Cellular location
Secreted
General function & pharmacology
Shows particularly broad specificity; although bonds involving phenylalanine and leucine are preferred, many others are also cleaved to some extent
Fibroblast growth factor 2
FGF2
agonist
inducer
Specific functionchemoattractant activity
Cellular location
Secreted
General function & pharmacology
Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4 .
PMID:8663044
Also acts as an integrin ligand which is required for FGF2 signaling .
PMID:28302677
Binds to integrin ITGAV:ITGB3 .
PMID:28302677
Plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration .
PMID:28302677 PMID:8663044
Functions as a potent mitogen in vitro .
PMID:1721615 PMID:3732516 PMID:3964259
Can induce angiogenesis .
PMID:23469107 PMID:28302677
Mediates phosphorylation of ERK1/2 and thereby promotes retinal lens fiber differentiation PMID:29501879
PMID:8663044
Also acts as an integrin ligand which is required for FGF2 signaling .
PMID:28302677
Binds to integrin ITGAV:ITGB3 .
PMID:28302677
Plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration .
PMID:28302677 PMID:8663044
Functions as a potent mitogen in vitro .
PMID:1721615 PMID:3732516 PMID:3964259
Can induce angiogenesis .
PMID:23469107 PMID:28302677
Mediates phosphorylation of ERK1/2 and thereby promotes retinal lens fiber differentiation PMID:29501879
Pro-epidermal growth factor
EGF
inducer
Specific functioncalcium ion binding
Cellular location
Membrane
General function & pharmacology
EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Can induce neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro PMID:10964941
Fibrinogen gamma chain
FGG
binder
Specific functioncell adhesion molecule binding
Cellular location
Secreted
General function & pharmacology
Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix. Has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization.
Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway.
Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways
Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway.
Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways
Scientific references(10)
Rees W.D.
Mechanisms of gastroduodenal protection by sucralfate.
The American Journal of Medicine
199191(2):S58-S63. doi: 10.1016/0002-9343(91)90452-4
Candelli M., Carloni E., Armuzzi A., Cammarota G., Ojetti V., Pignataro G., Santoliquido A., Pola R., Pola E., Gasbarrini G., Gasbarrini A.
Helicobacter pylori Infection and Migraine.
CNS Drugs
200013(2):97-101. doi: 10.2165/00023210-200013020-00003
Lam S.K.
Why Do Ulcers Heal with Sucralfate?.
Scandinavian Journal of Gastroenterology
199025(sup173):6-16. doi: 10.3109/00365529009091918
Bardhan K.D., Strugala V., Dettmar P.W.
Reflux revisited: advancing the role of pepsin.
International Journal Otolaryngol
20122012:646901. doi: 10.1155/2012/646901. Epub 2011 Nov 10
Szabo S.
The Mode of Action of Sucralfate: The 1×1×1 Mechanism of Action.
Scandinavian Journal of Gastroenterology
199126(sup185):7-12. doi: 10.3109/00365529109093214
Korman M.G., Bolin T.D., Szabo S., Hunt R.H., Marks I.N., Glise H.
Sucralfate: The Bangkok review.
Journal of Gastroenterology and Hepatology
19949(4):412-415. doi: 10.1111/j.1440-1746.1994.tb01264.x
Terao N., Yoshida N., Nagashima R.
Effects of Chloride and Sulfate Salts on the Inhibition or Promotion of Sucrose Crystallization in Initially Amorphous SucroseSalt Blends. doi: 10.1021/acs.jafc.
7b04746
s001
Patchett S.E., Enright H., Afdhal N., O'Connell W., O'Donoghue D.P.
Clot lysis by gastric juice: an in vitro study..
Gut
198930(12):1704-1707. doi: 10.1136/gut.30.12.1704
Gadacz T.R., Zuidema G.D.
Bile acid composition in patients with and without symptoms of postoperative reflux gastritis.
The American Journal of Surgery
1978135(1):48-52. doi: 10.1016/0002-9610(78)90008-9
Duane W.C., Wiegand D.M.
Mechanism by which bile salt disrupts the gastric mucosal barrier in the dog.
Journal Clinical Invest
1980 Nov66(5):1044-9. doi: 10.1172/JCI109932
ATC classification(1 code)
ATC A02BX02
Affected organisms(1)
Humans and other mammals
International brands(4)
Experimental properties(4)
Commercial products(139)
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Sucralfate
Additional database identifiers
Drugs Product Database (DPD)
2023
ChemSpider
32701653
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8887
GeneCards
PGA5
Guide to Pharmacology
2390
UniProt Accession
PEPA5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3676
GenAtlas
FGF2
GeneCards
FGF2
GenBank Gene Database
X04431
GenBank Protein Database
31362
UniProt Accession
FGF2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3229
GenAtlas
EGF
GeneCards
EGF
GenBank Gene Database
X04571
GenBank Protein Database
31121
UniProt Accession
EGF_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3661
GenAtlas
FGA
GeneCards
FGA
GenBank Gene Database
AF361104
GenBank Protein Database
13591824
UniProt Accession
FIBA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3662
GenAtlas
FGB
GeneCards
FGB
GenBank Gene Database
J00129
GenBank Protein Database
182430
UniProt Accession
FIBB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3694
GenAtlas
FGG
GeneCards
FGG
GenBank Gene Database
M10014
GenBank Protein Database
182439
UniProt Accession
FIBG_HUMAN
International reference pricing
11 formulations
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
From $0.11/ml
To $13.99/cup
Sulcrate Suspension Plus 200 mg/ml Suspension
$0.11/ml
Carafate 1 gm/10ml Suspension
$0.24/ml
Apo-Sucralfate 1 g Tablet
$0.31/tablet
Novo-Sucralate 1 g Tablet
$0.31/tablet
Nu-Sucralfate 1 g Tablet
$0.31/tablet
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
Show earlier publications
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
Source: go.drugbank.comCC BY-NC 4.0
Updated 26 days ago(8 Mar 2026)